Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL27858220 | 0.92 | CES2 (0.67) | TSHRALDH1A1CYP3A4CES2MEN1 | |
| Acetic Acid SCHEMBL28723481 | 0.92 | TSHR (0.59) | TSHRALDH1A1CYP3A4CES2ATM | |
| Acetic Acid SCHEMBL37245 | 0.92 | TSHR (0.59) | TSHRALDH1A1CYP3A4CES2ATM | |
| Acetic Acid SCHEMBL9616198 | 0.92 | TSHR (0.59) | TSHRALDH1A1CYP3A4CES2ATM | |
| Butoxyethanol SCHEMBL11512114 | 0.90 | TSHR (0.81) | TSHRALDH1A1CYP3A4CES2ATM | |
| Acetic Acid SCHEMBL14759095 | 0.89 | TSHR (0.56) | TSHRALDH1A1CYP3A4CES2ATM | |
| Acetic Acid SCHEMBL16761012 | 0.89 | TSHR (0.56) | TSHRALDH1A1CYP3A4CES2ATM | |
| Acetic Acid SCHEMBL4617603 | 0.89 | TSHR (0.56) | TSHRALDH1A1CYP3A4CES2ATM | |
| Acetic Acid SCHEMBL1996435 | 0.89 | TSHR (0.56) | TSHRALDH1A1CYP3A4CES2ATM | |
| Acetic Acid SCHEMBL29287060 | 0.89 | TSHR (0.56) | TSHRALDH1A1CYP3A4CES2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041885-A1 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-18 | — | — | US | claimed |
| WO-2009120746-A2 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-10-01 | — | — | WO | claimed |
| EP-0996430-B1 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES INC (US) | 2002-11-27 | — | — | EP | claimed |
| US-6451340-B1 | CRYSTALLINE ADEFOVIR DIPIVOXIL | GILEAD SCIENCES, INC. | 2002-09-17 | — | — | US | claimed |
| US-20020045599-A1 | Nucleotide analog compositions | GILEAD SCIENCES, INC. | 2002-04-18 | — | — | US | claimed |
| EP-0996430-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999004774-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| US-20100041885-A1 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-18 | — | — | US | disclosed |
| WO-2009120746-A2 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-10-01 | — | — | WO | disclosed |
| EP-1256584-B1 | Process for preparing Adefovir Dipivoxil | GILEAD SCIENCES INC (US) | 2004-09-29 | — | — | EP | disclosed |
| CN-1470517-A | Composition containing crystalline and non-crystalline Aide-diester and use thereof | 深圳信立泰药业有限公司 | 2004-01-28 | — | — | CN | disclosed |
| EP-0996430-B1 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1256585-A1 | Process fot preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine | GILEAD SCIENCES, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1256584-A1 | Process for preparing adefovir dipivoxil | GILEAD SCIENCES, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6451340-B1 | CRYSTALLINE ADEFOVIR DIPIVOXIL | GILEAD SCIENCES, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020045599-A1 | Nucleotide analog compositions | GILEAD SCIENCES, INC. | 2002-04-18 | — | — | US | disclosed |
| EP-0996430-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999004774-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041885-A1 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE | DPP4, DPP7, DPP9 | TSHR 3649/4885ALDH1A1 4140/4885CYP3A4 47/4885 |
| US-20020045599-A1 | Nucleotide analog compositions | NUDT1, PNP, TYMP | TSHR 4705/4885ALDH1A1 2736/4885CYP3A4 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.